Experimental pill aims to boost esophageal cancer treatment before surgery
NCT ID NCT06044311
First seen May 16, 2026 · Last updated May 21, 2026 · Updated 1 time
Summary
This study tests whether adding an experimental pill called vactosertib to standard chemotherapy and radiation can improve treatment for people with esophageal cancer. About 30 participants will take vactosertib for two weeks before and after standard therapy, then have scans and biopsies to see if the cancer responds. The goal is to find a more effective way to shrink tumors before surgery. The trial is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA ESOPHAGUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.